

Yoann Aldon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2313877/publications.pdf>

Version: 2024-02-01

19
papers

2,109
citations

687220

13
h-index

794469

19
g-index

25
all docs

25
docs citations

25
times ranked

5475
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	6.0	1,104
2	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228
3	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
4	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 1188-1200.e19.	13.5	154
5	Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. <i>Gene Therapy</i> , 2019, 26, 363-372.	2.3	137
6	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018, 24, 3324-3338.e5.	2.9	49
7	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, 6097.	5.8	38
8	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. <i>Cell Reports</i> , 2021, 35, 108933.	2.9	37
9	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. <i>Journal of Controlled Release</i> , 2019, 304, 65-74.	4.8	30
10	Identification of potential biomarkers of vaccine inflammation in mice. <i>ELife</i> , 2019, 8, .	2.8	25
11	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021, 7, 1863-1873.	5.3	20
12	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. <i>Journal of Controlled Release</i> , 2017, 249, 74-83.	4.8	18
13	Discrete partitioning of HIV-1 Env forms revealed by viral capture. <i>Retrovirology</i> , 2015, 12, 81.	0.9	16
14	Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 483-493.	2.3	13
15	Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non-antigen-Specific B and T Cells to the Intestinal and Genital Mucosae. <i>Journal of Immunology</i> , 2020, 204, 903-913.	0.4	8
16	The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate. <i>Aids</i> , 2021, 35, 1907-1917.	1.0	5
17	CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice. <i>Journal of Controlled Release</i> , 2016, 232, 75-82.	4.8	4
18	Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates. <i>IScience</i> , 2022, 25, 104101.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2